{"id":"NCT05158140","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine With a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-01-12","primaryCompletion":"2023-02-21","completion":"2023-02-21","firstPosted":"2021-12-15","resultsPosted":"2024-02-13","lastUpdate":"2025-07-18"},"enrollment":850,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infection"],"interventions":[{"type":"BIOLOGICAL","name":"V110","otherNames":["PNEUMOVAX™23","23-Valent Pneumococcal Polysaccharide Vaccine"]},{"type":"BIOLOGICAL","name":"V114","otherNames":["VAXNEUVANCE™","15-Valent Pneumococcal Conjugate","Vaccine"]},{"type":"BIOLOGICAL","name":"mRNA-1273","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo for V110","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo for V114","otherNames":[]}],"arms":[{"label":"V110 Concomitant with mRNA-1273 (V110 Concomitant)","type":"EXPERIMENTAL"},{"label":"V110 Nonconcomitant with mRNA-1273 (V110 Nonconcomitant)","type":"EXPERIMENTAL"},{"label":"V114 Concomitant with mRNA-1273 (V114 Concomitant)","type":"EXPERIMENTAL"},{"label":"V114 Nonconcomitant with mRNA-1273 (V114 Nonconcomitant)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine (V110) for the prevention of pneumococcal disease, or a 15-valent pneumococcal conjugate vaccine (V114) indicated for the prevention of invasive pneumococcal disease.","primaryOutcome":{"measure":"Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Among Participants Administered V110","timeFrame":"Up to Day 7 After Any Vaccination (Up to Study Day 37)","effectByArm":[{"arm":"V110 Concomitant With mRNA-1273 (V110 Concomitant)","deltaMin":18.7,"sd":null},{"arm":"V110 Nonconcomitant With mRNA-1273 (V110 Nonconcomitant)","deltaMin":14.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":46,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["40006738"],"seeAlso":["https://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26095&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":214},"commonTop":["Injection site pain","Fatigue","Headache","Injection site swelling","Myalgia"]}}